{
  "docId": "019de515-46e8-778b-9aa2-edc9d4857990",
  "docSlug": "9b80ae10198fa4f452f4044732defb94",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 17 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 17,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-46e8-778b-9aa2-edc9d4857990/16",
  "deckHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990",
  "deckJsonHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990.json",
  "deckAnchorHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.88,
        "x": 0.08,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Prepare/Isolate Concentrate Culture Cryopreserve Thaw/Dose",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1819e5b-a5a8-424e-941b-76391557c892",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.039,
        "w": 0.158,
        "x": 0.806,
        "y": 0.055
      },
      "kind": "image",
      "text": "MaxCyte®",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3c9124b-c7b1-4def-af75-dbdb019a3182",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.36,
        "w": 0.459,
        "x": 0.506,
        "y": 0.489
      },
      "kind": "list",
      "text": "Initial 2023 guidance for total revenue growth 21% to 26% over 2022, including core revenue growth of 20% to 25% and SPL program-related revenue of approximately $6 million\nContinue to launch new PAs to address customer needs around scale and throughput\nContinue to build out in-house manufacturing capacity and invest in manufacturing automation to enable innovation in cell therapy\nControlled launch of the VLx to develop use cases in applications and cell types\nEvaluate opportunities that are an expansion of the core technology including process analytics and product characterization",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18120603-471e-4332-9013-07aeb13fc937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.306,
        "w": 0.44,
        "x": 0.039,
        "y": 0.489
      },
      "kind": "list",
      "text": "Added 3 new SPL partnerships in 2022 including Intima Biosciences in February, LG Chem in July and Curamys in December\nSigned an SPL partnership with Vertex upon Vertex obtaining the clinical and commercial rights to use MaxCyte's technology for the development of exa-cel (formerly known as CTX001)\nCompleted move into new HQ; more than triples manufacturing space and adds additional process development facilities\nLaunched the VLx at BPI Conference in September 2022 to support the use in large-scale bioprocessing applications",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb97a28e-7f21-477c-9b25-56c885ac551c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.023,
        "w": 0.301,
        "x": 0.609,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "2023 Guidance and 2023+ Outlook",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89182cee-a483-4a9b-8d9a-30bcf4adb3d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.023,
        "w": 0.22,
        "x": 0.17,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "2022 Achievements",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf65d5eb-bf63-4f50-af12-8240595f3772",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.011,
        "w": 0.018,
        "x": 0.49,
        "y": 0.963
      },
      "kind": "source-note",
      "text": "16",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5d08e4f-a2ff-4530-ab86-6ca76ceb3ebf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.011,
        "w": 0.15,
        "x": 0.823,
        "y": 0.963
      },
      "kind": "source-note",
      "text": "© 2023 MaxCyte, Inc. All Rights Reserved",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f67c4271-788d-4e50-a902-aadd276dd974",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.54,
        "x": 0.039,
        "y": 0.06
      },
      "kind": "title",
      "text": "2022 Summary and Outlook for 2023+",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9634baf5-91f1-484c-9c29-b9f08c075bec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}